New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 20, 2014
08:04 EDTPOZN, PTX, GSKPOZEN announces U.S. rights for Treximet acquired by Pernix Therapeutics
POZEN (POZN) announced that the acquisition of all of GlaxoSmithKline’s (GSK) rights to Treximet have been acquired by Pernix Therapeutics Holdings (PTX). The previously announced transaction was contingent upon Pernix securing financing, which is now complete. As part of the divestiture, GSK has assigned the Product Development and Commercialization Agreement between POZEN and GSK to Pernix, and POZEN and Pernix have amended the agreement to address rights of the parties and future development. Under the amended agreement, Pernix will continue certain of GSK’s ongoing development activities and undertake certain new activities, for which POZEN will provide reasonable assistance. In addition, any restrictions on POZEN’s right to develop and commercialize additional certain dosage forms of sumatriptan / naproxen combinations outside of the United States have been eliminated, and POZEN may seek approval for these combinations on the basis of the approved U.S. New Drug Application. Pernix had also granted POZEN a warrant to purchase 500,000 shares of Pernix common stock at an exercise price equal to the closing market price on May 13, 2014. The common stock underlying the warrant will be registered by Pernix with the Securities and Exchange Commission. The warrant will be exercisable from August 20, 2014, the closing date of the divestiture, until February 28, 2018.
News For POZN;PTX;GSK From The Last 14 Days
Check below for free stories on POZN;PTX;GSK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
05:58 EDTGSKGlaxoSmithKline to pay GBP 297M fine to Chinese government
Subscribe for More Information
September 17, 2014
14:57 EDTGSKProsensa announces commencement of re-dosing of drisapersen
Subscribe for More Information
07:39 EDTGSKMorningstar to hold a conference
Management Behind the Moat Conference to be held in Chicago on September 17-18.
September 16, 2014
07:33 EDTGSKMylan initiates Phase III clinical trials for Advair Diskus and Lantus
Mylan (MYL) announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's (GKS) Advair Diskus and its insulin analog to Sanofi's (SNY) Lantus. In October Mylan will commence a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma patients.
07:31 EDTGSKEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 15, 2014
16:10 EDTGSKFive Prime announces option exercise by GlaxoSmithKline to obtain license
Subscribe for More Information
07:27 EDTGSKIBC Life Sciences to hold a conference
Subscribe for More Information
September 10, 2014
09:58 EDTGSKGlaxoSmithKline has a conference call hosted by JPMorgan
Subscribe for More Information
September 9, 2014
06:25 EDTGSKDocuments show DOJ probed GSK China unit in 2012, Reuters says
Internal documents revealed that a U.S. anti-bribery investigation into GlaxoSmithKline (GSK) touched on the firm's Chinese consumer healthcare division two years ago, which infers that the company's compliance issues in the country could be broader than initially discovered, according to Reuters, citing the documents. Reference Link
September 8, 2014
08:48 EDTGSKGilead announces AMBITION study results in collaboration with Glaxo
Subscribe for More Information
September 7, 2014
13:57 EDTGSKGlaxoSmithKline Ebola vaccine works in tests on monkeys, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use